Table I.
Correlation between clinicopathological factors, DFS and OS in 104 primary breast tumors of luminal type.
| Clinicopathological factors | No. of cases | DFS
|
OS
|
||
|---|---|---|---|---|---|
| Wald statistic | P-value | Wald statistic | P-value | ||
| Age (years) | 4.786 | 0.680 | 5.865 | 0.566 | |
| ≤50 | 48 | ||||
| >50 | 56 | ||||
| Menopausal status | 2.735 | 0.541 | 3.100 | 0.432 | |
| Premenopausal | 59 | ||||
| Postmenopausal | 45 | ||||
| T | 4.313 | 0.040 | 2.495 | 0.023 | |
| T1 | 19 | ||||
| T2 | 57 | ||||
| T3 | 24 | ||||
| T4 | 4 | ||||
| N | 17.467 | 0.002 | 23.220 | 0.000 | |
| N0 | 48 | ||||
| N1 | 27 | ||||
| N2 | 17 | ||||
| N3 | 12 | ||||
| ER | 3.133 | 0.372 | 4.319 | 0.229 | |
| − | 3 | ||||
| + | 10 | ||||
| ++ | 25 | ||||
| +++ | 66 | ||||
| PR | 1.427 | 0.699 | 2.051 | 0.562 | |
| − | 23 | ||||
| + | 23 | ||||
| ++ | 23 | ||||
| +++ | 35 | ||||
| HER-2 | 4.174 | 0.041 | 2.598 | 0.107 | |
| Negative | 47 | ||||
| Postive | 57 | ||||
| p-ERα-S118 | 1.686 | 0.194 | 2.882 | 0.090 | |
| Negative | 78 | ||||
| Postive | 26 | ||||
| p-ERα-S167 | 1.738 | 0.187 | 0.989 | 0.320 | |
| Negative | 76 | ||||
| Postive | 28 | ||||
DFS, disease-free survival; OS, overall survival; T, tumor size; N, axillary lymph node staging; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; p-ERα-S118, estrogen receptor α phosphorylation at serine 118; p-ERα-S167, estrogen receptor α phosphorylation at serine 167;
−,
negative;
+,
weakly positive;
++,
moderately positive;
+++,
strongly positive.